RESUMO
Haemostasis may be implicated in the pathogenesis of various thrombotic disease. Assay of natural coagulation inhibitors [AT III and PC] in coronary heart diseases may be informative in such cases. In this work, AT III and PC were assayed for 23 patients with coronary ischaemia and infarction besides 12 controls. A highly significant reduction in AT III had been observed in patient groups which had been attributed to an activated coagulation mechanism with consequent consumption of AT III. On the other hand, a significant increase in PC activity had been observed in both studied groups. This rise may be a body attempt to overcome hypercoagulability in those patients. We recommend a trial to use AT III and recombinant APC as therapeutic lines in patients with coronary heart diseases